Publication:
Immune response to Covid-19 mRNA vaccination in previous nonresponder kidney transplant recipients after short-term withdrawal of mycophenolic acid 1 and 3 months after an additional vaccine dose

dc.contributor.coauthorKuehn, Tessa
dc.contributor.coauthorSpeer, Claudius
dc.contributor.coauthorMorath, Christian
dc.contributor.coauthorBartenschlager, Marie
dc.contributor.coauthorKim, Heeyoung
dc.contributor.coauthorBeimler, Joerg
dc.contributor.coauthorBuylaert, Mirabel
dc.contributor.coauthorNusshag, Christian
dc.contributor.coauthorKaelble, Florian
dc.contributor.coauthorReineke, Marvin
dc.contributor.coauthorToellner, Maximilian
dc.contributor.coauthorKlein, Katrin
dc.contributor.coauthorBlank, Antje
dc.contributor.coauthorParthe, Sylvia
dc.contributor.coauthorSchnitzler, Paul
dc.contributor.coauthorZeier, Martin
dc.contributor.coauthorBartenschlager, Ralf
dc.contributor.coauthorTran, Thuong Hien
dc.contributor.coauthorSchaier, Matthias
dc.contributor.coauthorBenning, Louise
dc.contributor.departmentTIREX (Koç University Transplant Immunology Research Centre of Excellence)
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSüsal, Caner
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:40:44Z
dc.date.issued2023
dc.description.abstractBackground: The impaired immune response to coronavirus disease 2019 (Covid-19) vaccination in kidney transplant recipients (KTRs) leads to an urgent need for adapted immunization strategies. Methods: Sixty-nine KTRs without seroconversion after =3 Covid-19 vaccinations were enrolled, and humoral response was determined after an additional full-dose mRNA-1273 vaccination by measuring severe acute respiratory syndrome coronavirus 2-specific antibodies and neutralizing antibody activity against the Delta and Omicron variants 1 and 3 mo postvaccination. T-cell response was analyzed 3 mo postvaccination by assessing interferon-? release. Mycophenolic acid (MPA) was withdrawn in 41 KTRs 1 wk before until 4 wk after vaccination to evaluate effects on immunogenicity. Graft function, changes in donor-specific anti-HLA antibodies, and donor-derived cell-free DNA were monitored in KTRs undergoing MPA withdrawal. Results: Humoral response to vaccination was significantly stronger in KTRs undergoing MPA withdrawal 1 mo postvaccination; however, overall waning humoral immunity was noted in all KTRs 3 mo after vaccination. Higher anti-S1 immunoglobulin G levels correlated with better neutralizing antibody activity against the Delta and Omicron variants, whereas no significant association was detected between T-cell response and neutralizing antibody activity. No rejection occurred during study, and graft function remained stable in KTRs undergoing MPA withdrawal. In 22 KTRs with Omicron variant breakthrough infections, neutralizing antibody activity was better against severe acute respiratory syndrome coronavirus 2 wild-type and the Delta variants than against the Omicron variant. Conclusions: MPA withdrawal to improve vaccine responsiveness should be critically evaluated because withdrawing MPA may be associated with enhanced alloimmune response, and the initial effect of enhanced seroconversion rates in KTRs with MPA withdrawal disappears 3 mo after vaccination.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.openaccessGreen Published, Bronze
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis study received funding for kits and supplies for dd-cfDNA testing from CareDx Inc (Brisbane, CA). The funding source had no role in study design, data collection, and analysis.
dc.description.volume107
dc.identifier.doi10.1097/TP.0000000000004516
dc.identifier.eissn1534-6080
dc.identifier.issn0041-1337
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85153897355
dc.identifier.urihttps://doi.org/10.1097/TP.0000000000004516
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23420
dc.identifier.wos978303100026
dc.keywordsAntibodies
dc.keywordsNeutralizing
dc.keywords Viral
dc.keywordsCovid-19
dc.keywordsHumans
dc.keywordsImmunity
dc.keywordsHumoral
dc.keywords Kidney transplantation
dc.keywordsMycophenolic acid
dc.keywordsSars-Cov-2
dc.keywordsSars-Cov-2 variants
dc.keywordsTransplant recipients
dc.keywordsVaccination
dc.keywordsVaccines
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.grantnoCareDx Inc (Brisbane, CA).
dc.relation.ispartofTransplantation
dc.subjectImmunology
dc.subjectSurgery
dc.subjectTransplantation
dc.titleImmune response to Covid-19 mRNA vaccination in previous nonresponder kidney transplant recipients after short-term withdrawal of mycophenolic acid 1 and 3 months after an additional vaccine dose
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSüsal, Caner
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2TIREX (Koç University Transplant Immunology Research Centre of Excellence)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublication29cd9ca5-6407-4582-92b6-788bc6f33efd
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery29cd9ca5-6407-4582-92b6-788bc6f33efd
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files